Eagle Pharmaceuticals Profit Margin

The latest profit margin for EGRX is 4.64% as of June 2023. That compares with 8.37% in the prior-year period — down 44.6% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Eagle Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, EGRX's profit margin moved from 8.37% to 4.64% — a 44.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eagle Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, EGRX currently prints 4.64% for profit margin, while the sector average sits near 13.89%. That is roughly 66.6% below the sector mean. Large gaps often invite a closer look at Eagle Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Eagle Pharmaceuticals converts resources into returns. At 4.64%, EGRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 8.37% in the prior-year period — down 44.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting EGRX's profit margin (4.64%), review year-over-year change from 8.37%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.